Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:21:40.350Z.
Calculation as of: 2026-10-06T16:21:40.350Z.
Quote observation: 2026-10-06T16:20:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5275dea95979b783385bf47589e59696b88cb0a7810ad834bc8fbd7b091458bc
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
CNS Pharmaceuticals, Inc.
Market Cap
$7.29M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| CNS Pharmaceuticals, Inc. (CNSP) | $7.29M | N/A |
| Longeveron Inc. (LGVN)vs › | $7.36M | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.20M | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.71M | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.08M | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.07M | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.16M | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $7.86M | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.76M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
